Avoid common mistakes on your manuscript.
Correction to: Adv Ther (2022) 39:1068–1080 https://doi.org/10.1007/s12325-021-01981-7
The third author surname has been corrected as Xuãn-Lan Lam Hoai.
The original article has been corrected.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Qualified researchers may request data from Amgen clinical studies. Complete details are available at the following: https://www.amgen.com/science/clinical-trials/clinical-data-transparencypractices/clinical-trial-data-sharing-request.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Ghislain, PD., Lambert, J., Lam Hoai, XL. et al. Correction to: Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study. Adv Ther 40, 3279–3280 (2023). https://doi.org/10.1007/s12325-023-02542-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-023-02542-w